Health Beat: Stem cell therapy for osteoarthritis – WFMZ Allentown

Health Beat: Stem cell therapy for...

CHICAGO - As a professional photographer, climbing up step ladders and walking down stairs are part of the daily grind for 65-year-old Linda Schwartz.

"There's constant activity; you're moving the whole time, really," Schwartz said

But the pain of osteoarthritis in both of her knees was making all that activity a little harder.

"I tried cortisone shots. I had something called Euflexxa," Schwartz detailed. "I was sent to physical therapy twice. I mean, I did try acupuncture in my knees, but it didn't really seem to make a difference."

"It's like the rubber on the tire, so as you start to lose the rubber in your tire and the rim hits the road, that's what happens when you have bone on bone arthritis and you've lost all the cartilage in your knee," explained Dr. Adam Yanke, an orthopedic surgeon at Rush University Medical Center in Chicago.

Yanke enrolled Schwartz in an experimental new therapy that involved injecting amniotic fluid that contained stem cells donated by healthy mothers into the knees of osteoarthritis patients.

"Between the two of those, they're a potent anti-inflammatory and they also have growth factors that help promote healing or healthy growth of tissue," Yanke said.

It was, by far, the most effective pain treatment that Schwartz has tried. Unlike cortisone shots, there are no side-effects. The pain relief has so far lasted up to a year.

Research summary - Stem cell therapy for osteoarthritis

"It was a very gradual feeling of it's a little bit better, it's a little bit better, and then realizing, wow, it's really pretty good," said Schwartz.

The one drawback is the therapy is not for patients whose arthritis is so bad it requires knee replacement surgery. Even though it's still in the experimental stage, Yanke offers the stem cell treatment to his patients, but at a cost of $2,200 a shot, it is not yet covered by insurance.

Go here to read the rest:
Health Beat: Stem cell therapy for osteoarthritis - WFMZ Allentown

Angels’ Garrett Richards Among Pitchers Using Stem Cell Treatment Over Tommy John Surgery – CBS Local


CBS Local
Angels' Garrett Richards Among Pitchers Using Stem Cell Treatment Over Tommy John Surgery
CBS Local
This, combined with new advances in stem cell technology, gave Richards the option to avoid going under the knife and instead undergo stem cell treatment. This and much more on the topic of stem cell research and its role in baseball was revealed in a ...

and more »

Originally posted here:
Angels' Garrett Richards Among Pitchers Using Stem Cell Treatment Over Tommy John Surgery - CBS Local

Risky treatment can stop multiple sclerosis for years – BBC News


BBC News
Risky treatment can stop multiple sclerosis for years
BBC News
A multiple sclerosis treatment being tested in patients can stop the disease for at least five years, say doctors. The risky therapy involves wiping out the person's immune system with strong cancer drugs and then rebooting it with a stem cell ...
Radical stem cell treatment for MS could stop the disease in its tracks for 5 years and even allow some sufferers to ...Daily Mail
Stem Cell Transplants May Help Some With Multiple SclerosisDoctors Lounge
Resetting the Immune System, A Risky Treatment But Proven Solution To Stop Multiple Sclerosis For 5 YearsScience Times
Edition Time -iTech Post
all 25 news articles »

Read the original here:
Risky treatment can stop multiple sclerosis for years - BBC News

Better Stem Cell Tx Outcomes for Younger MS Patients – Doctors Lounge

Category: Neurology | Pathology | Journal

Back to Journal Articles

Results support additional trials of autologous hematopoietic stem cell transplantation

Comments: (0)

Tell-a-Friend

MONDAY, Feb. 20, 2017 (HealthDay News) -- Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the disease, but selecting the right patients for the treatment is key, according to a study published online Feb. 20 in JAMA Neurology.

Riccardo Saccardi, M.D., from the cell therapy and transfusion medicine unit at Careggi University Hospital in Florence, Italy, and colleagues followed 281 patients with predominantly progressive forms of MS. The patients were from 13 countries and all had undergone autologous hematopoietic stem cell transplant between 1995 and 2006.

The researchers found that 46 percent of the patients experienced progression-free survival at five years after transplant. Younger patients with a relapsing form of MS who were not severely disabled and who hadn't found relief with other treatments fared better than others over five years. Within 100 days of transplant, eight patients died (2.8 percent). The researchers believe these deaths were most likely due to the transplant technology used before 2006, which has since improved.

"Stem cell transplantation cannot be considered a cure for MS," Saccardi told HealthDay. "However, it can be considered a concrete option for patients showing aggressive MS who have not responded to approved treatments."

More than one author disclosed financial ties to pharmaceutical and biotechnology companies, several of which contributed funding for the study.

Abstract/Full Text Editorial (subscription or payment may be required)

View original post here:
Better Stem Cell Tx Outcomes for Younger MS Patients - Doctors Lounge

Connecting the Dots: Stem Cells Provide Valuable Tool for Linking Genes and Disease – Memorial Sloan Kettering Cancer Center (blog)

Summary

MSK researchers are using pluripotent stem cells to create models of disease in the pancreas, including diabetes and pancreatic cancer.

Highlights

The ability to isolate and grow pluripotent stem cells has offered many new opportunities for biological and medical research since the technique was first developed about 20 years ago. These cells are remarkable because they have the ability to develop into any type of cell in the body from liver cells to nerve cells to heart cells and more.

The field of regenerative medicine is based on the premise that doctors may eventually be able to engineer stem cells to replace tissues that have been lost due to injury or disease. Increasingly, pluripotent stem cells are also proving to be a valuable tool in the lab, especially for studying how genetic changes affect cell growth and division.

In a new study published February 9 in the journal Cell Stem Cell, a team of researchers led by Memorial Sloan Kettering developmental biologist Danwei Huangfu has demonstrated the value of using pluripotent stem cells to study how pancreatic cells form in a person. Their research has implications for the study of diabetes a disease characterized by dysfunction in certain types of pancreas cells as well as pancreatic cancer.

A gene-editing technology called CRISPR/Cas9 allows scientists to study the effects of specific molecular changes.

Many diseases have been difficult to recreate in animal models like mice, which makes it hard for us to study them, Dr. Huangfu says. Using pluripotent stem cells to create pancreas cells in a dish is teaching her lab members about the role certain genes play in pancreatic diseases and may lead to new kinds of treatments.

In the new study, the investigators looked at the function of a gene called GATA6 in pancreas cells. In humans, mutations in this gene can cause a range of medical problems that result from the inability of the pancreas to develop and function normally.

To study the gene, the team used a gene-editing technology called CRISPR/Cas9, which acts like a molecular scissors and enables researchers to make precise changes to DNA. Specifically, the MSK researchers used the technology to create pancreas cells that had only one copy of the GATA6 gene rather than the normal two copies, a state called haploinsufficiency. This situation is similar to what is seen in some forms of diabetes.

Our research illustrates the important contribution that human pluripotent stem cells can make in studying common but complex diseases.

Danwei Huangfu developmental biologist

Recreating these defective pancreas cells in a dish has already enabled the researchers to make new discoveries about GATA6 and its interaction with another gene called GATA4 in pancreatic defects, some of which they report in the Cell Stem Cell paper.

We believe this is the first study in human pluripotent stem cells to look beyond diseases caused by relatively rare single-gene mutations, Dr. Huangfu says. Our research illustrates the important contribution that human pluripotent stem cells can make in studying common but complex diseases characterized by multiple genetic factors as well as by potential environmental factors.

Dr. Huangfus lab is also using gene editing to study the formation of cancer in the pancreas. Because MSK sequences many of our patients tumors, we know a lot about the mutations that are present in cancer, she says. But we dont always know which ones are important.

In cancer, genetic changes in tumors are categorized as driver mutations errors that are important for the formation and growth of tumors or passenger mutations, which just go along for the ride.

Doing experiments with cancer genes inserted into these pancreas models helps us understand the cellular basis of the disease, and to separate the drivers from the passengers, Dr. Huangfu explains. Then we can work toward developing better diagnostic methods and treatments for cancer, based on knowing which mutations come first and which are the most important.

More:
Connecting the Dots: Stem Cells Provide Valuable Tool for Linking Genes and Disease - Memorial Sloan Kettering Cancer Center (blog)

Early-stage study validates Cellect Bio’s method of stem cell selection; shares ahead 19% – Seeking Alpha

Thinly traded nano cap Cellect Biotechnology Ltd. (APOP +19.4%) jumps on more than a 4x surge in volume in response to its announcement of positive results from a Phase 1 study aimed at validating its proprietary method of stem cell selection called ApoGraft. The process allows for the natural enrichment of stem cells that can be used in cell therapies or transplantation with significantly less risk of rejection.

The study was conducted on blood stem cells donated by 104 healthy subjects. Each sample represented a 5% graft. ApoGraft, used for only a few hours, produced a significant increase in the death of mature immune cells without compromising the quality and quantity of stem cells.

The Companys technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells for in quantity and quality that will allow stems cell-related treatments and procedures. Cellects technology is applicable to a wide variety of stem cells related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations.

Read the original post:
Early-stage study validates Cellect Bio's method of stem cell selection; shares ahead 19% - Seeking Alpha

BrainStorm seeks early approval for stem cell treatment in Canada – Reuters

TEL AVIV Israel's BrainStorm Cell Therapeutics is seeking early approval in Canada for its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), a neuro-degenerative disease, even before it completes late-stage clinical trials.

BrainStorm said on Tuesday that it had signed an agreement with CCRM, a Canadian not-for-profit organization that supports development of regenerative medicine, to support a market authorization request for its ALS treatment, called NurOwn.

CCRM is helping BrainStorm meet requirements for the Canadian health regulator's early access pathway, which provides rapid review for drugs to treat serious or life-threatening conditions.

If NurOwn qualifies, it could be authorized in Canada for distribution by the start of 2018, the company said.

"We seemingly fit the criteria," BrainStorm Chief Executive Chaim Lebovits told Reuters.

At the same time, BrainStorm will conduct a Phase 3 clinical trial for NurOwn at multiple sites in the United States and Israel. The company in December said the advanced clinical trial is expected to begin enrolling patients in the second quarter of 2017.

BrainStorm also plans to submit an application in Israel that will allow patient access to NurOwn as a treatment that has been granted "Hospital Exemption". This recently approved pathway would permit BrainStorm to partner with a medical center in Israel and be allowed to treat patients with NurOwn for a fee.

Lebovits foresees possible treatments under this pathway as early as the second half of 2017.

BrainStorm is also examining whether it may be eligible for early approval in the United States under new legislation passed in December that supporters say will speed access to new drugs.

According to the ALS Association, 5,600 people in the United States are diagnosed each year with the disease, also known as Lou Gehrig's Disease, which has severely disabled British physicist Stephen Hawking.

(Reporting by Tova Cohen; Editing by Mark Potter)

WASHINGTON Virginia Governor Terry McAuliffe on Tuesday vetoed a bill that would have blocked funding for Planned Parenthood, which provides abortions and other health services.

CHICAGO Tyson Foods Inc in June will switch its retail line of company-branded chicken products to birds raised without any antibiotics, a top executive said on Tuesday, accelerating the meat sector's shift away from the drugs.

GENEVA China has detected an evolution in the H7N9 avian flu virus that is capable of causing severe disease in poultry and requires close monitoring, the World Health Organization (WHO) said on Tuesday.

More:
BrainStorm seeks early approval for stem cell treatment in Canada - Reuters

Cellect Announces Positive Clinical Trial Results – P&T Community

Cellect Announces Positive Clinical Trial Results
P&T Community
The Company's technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells for in quantity and quality that will allow stems cell related treatments and procedures. Cellect's ...

and more »

Originally posted here:
Cellect Announces Positive Clinical Trial Results - P&T Community

Nanofiber Matrix Improves Stem Cell Growth – Asian Scientist Magazine

When grown on a fiber-on-fiber matrix, 95 percent of the pluripotent stem cells formed colonies.

Asian Scientist Newsroom | February 22, 2017 | In the Lab

AsianScientist (Feb. 22, 2017) - A nanofiber-on-microfiber matrix could help produce more and better quality stem cells for disease treatment and regenerative therapies, according to a study published in Biomaterials.

Developed by a team of researchers led by Ken-ichiro Kamei, an associate professor at Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS), the fiber-on-fiber (FF) matrix improves on currently available stem cell culturing techniques.

Researchers have been developing 3D culturing systems to allow human pluripotent stem cells (hPSCs) to grow and interact with their surroundings in all three dimensions, as they would inside the human body, rather than in two dimensions, like they do in a petri dish. However, most currently reported 3D culturing systems have limitations, and result in low quantities and quality of cultured cells.

Kamei and his colleagues fabricated gelatin nanofibers onto a microfiber sheet made of synthetic, biodegradable polyglycolic acid. Human embryonic stem cells were then seeded onto the matrix in a cell culture medium.

The FF matrix allowed easy exchange of growth factors and supplements from the culture medium to the cells. Also, the stem cells adhered well to the matrix, resulting in robust cell growth: after four days of culture, more than 95 percent of the cells grew and formed colonies.

The team also scaled up the process by designing a gas-permeable cell culture bag in which multiple cell-loaded, folded FF matrices were placed. The system was designed so that minimal changes were needed to the internal environment, reducing the amount of stress placed on the cells. This newly developed system yielded a larger number of cells compared to conventional 2D and 3D culture methods.

Our method offers an efficient way to expand hPSCs of high quality within a shorter term, the authors said.

Also, because the use of the FF matrix is not limited to a specific type of culture container, it allows for scaling up production without loss of cell functions.

Additionally, as nanofiber matrices are advantageous for culturing other adherent cells, including hPSC-derived differentiated cells, FF matrix might be applicable to the large-scale production of differentiated functional cells for various applications, the researchers concluded.

The article can be found at: Liu et al. (2017) Nano-on-micro Fibrous Extracellular Matrices for Scalable Expansion of Human ES/iPS Cells.

Source: Kyoto University. Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Go here to read the rest:
Nanofiber Matrix Improves Stem Cell Growth - Asian Scientist Magazine

Amazing medicine – The News International

If we cut off the tail of a lizard, it grows back. If we cut off the hand of a human being, it does not grow back. Why not? This question has perplexed scientists for a long time. Recently scientists at the Translational Genomics Research Institute (TGen) and Arizona State University (ASU) in the US identified three tiny RNA switches (known as microRNAs) which turn genes on and off and are responsible for the regeneration of tails in the green lizard. Now researchers are hoping that using the next generation genomic DNA and computer analysis will lead to discoveries of new therapeutic approaches to switch on similar regenerative genes in human beings.

Micro RNAs are able to control many genes at the same time. They have been compared to an orchestra conductor controlling and directing many musicians. Hundreds of genes (musicians playing the orchestra of life), controlled by a few micro RNA switches, have been identified that are responsible in the regenerative process. This may well mark the beginning of a new era in which it may be possible to regenerate cartilage in knees, repair spinal cords and amputated limbs.

Tissue regeneration has become an attractive field of science, triggered by exciting advances in stem cell technologies. Stem cells are undifferentiated biological cells that are then converted into various types of cells such as heart, kidney or skin through a process known as differentiation. They can divide into more stem cells and provide a very effective mechanism for repair of damaged tissues in the body. The developing embryo contains stem cells which are then transformed into specialised cells as the embryo develops. They can be obtained by extraction from the bone marrow, adipose tissue or blood, particularly the blood from the umblical cord after birth.

Stem cells are now finding use in a growing number of therapies. For instance leukaemia is a cancer of the white blood cells. To treat leukaemia, one approach is to get rid of the diseased white blood cells and replace them with healthy cells. This may be done by a bone marrow transplant through which the patients bone marrow stem cells are replaced with those from a healthy, matching donor. If the transplant is successful, the stem cells migrate into the patients bone marrow resulting in the production of new, healthy white blood cells that replace the abnormal cells. Stem cells can now be artificially grown and then transformed (differentiated) into the heart, kidney, nerve or other typed of cells.

The field of regenerative medicine is developing at a fast pace. It involves the replacement, engineering or regeneration of human tissues and organs so that their normal function can be restored. Tissues and organs can also be grown in the laboratory if the body cannot heal itself. If the cells of the organ being grown are derived from the patients own cells, the possibility of rejection of the transplanted organ is minimised. Stem cells may also be used to regenerate organs.

Each year about 130,000 organs, mostly kidneys, are transplanted from one human being to another. The process of growing organs artificially has been greatly accelerated by the advent of 3D bioprinting. This involves the use of 3D printing technologies through which a human organ, liver or kidney, is produced by printing it with cells, layer-by-layer. This became possible when it was discovered that human cells can be sprayed through the nozzles of an inkjet printer without destroying or damaging them. Tissues and organs can thus be produced and transplanted into humans. Joints, jaw bones and ligaments can also be produced in this manner.

Initially, the work was confined to animals when ears, bones and muscle tissues were produced by bioprinting and then successfully transplanted into animals. Even prosthetic ovaries of mice were produced and transplanted so that the recipient mice could conceive and give birth later. While gonads have not been produced by bioprinting in humans, blood vessels have already been produced by the printing process and successfully transplanted into monkeys. Considerable work is also going on in the production of human knee cartilage pads through the bioprinting process. Wear and tear of the cartilage results in difficulties in walking, particular in older age groups, and often requires knee replacement through surgeries. The development of technologies to replace the damaged cartilages with new cartilages made by bioprinting could prove to be invaluable.

Another area of active research in this field is the production of human skin by bioprinting which may be used for treating burns and ulcers. Technologies have been developed to spray stem cells derived from the patient directly on the areas of the body where the skin is needed. In this way, stem cells help skin cells regrow under suitable conditions. Similar progress is being made in generating liver, kidney and heart tissues so that the long waiting time for donors can be circumvented.

When will we be able to print entire human organs? It has been estimated that complete human kidneys and livers should become commercially available through the bioprinting process within five to seven years. Hearts will probably take longer because of their more complex internal structure. However, one thing is clear: a huge revolution is now taking place in the field of regenerative medicine, triggered by spectacular advances in stem cell research. This presents a wonderful opportunity for learning and developing expertise in this field for us in our country.

In Pakistan a number of important steps have been taken in this fast evolving field. One of them is the establishment of a first rate facility for stem cell research in the Dr Panjwani Centre for Molecular Medicine and Drug Research (PCMD) in the University of Karachi. This institution has already earned an international reputation because of its outstanding publications in this field.

A second important development is that plans to set up an Institute for Translational Regenerative Medicine at PCMD so that Pakistan remains at the cutting edge in this fast emerging field are now under way.

Such initiatives can however only contribute to the process of socio-economic development if they operate under an ecosystem that is designed to promote the establishment of a strong knowledge economy.

Pakistan spends only about 0.3 percent of its GDP on science and about two percent of its GDP on education, bringing the nations ranking to the lowest 10 countries in the world. This is largely due to the stranglehold of the feudal system over our democracy. It is only by tapping into our real wealth our children that Pakistan can emerge from the quagmire of illiteracy and poverty and stand with dignity in the comity of nations.

The writer is chairman of UN ESCAP Committee on Science Technology & Innovation and former chairman of the HEC. Email: [emailprotected]

Read more:
Amazing medicine - The News International